We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Philips to Acquire Adac Laboratories for $426 Million

By HospiMedica staff writers
Posted on 20 Nov 2000
Royal Philips Electronics (Amsterdam, The Netherlands) has agreed to acquire Adac Laboratories (Milpitas, CA, USA) for around US$426 million. The acquisition will enable Philips Medical Systems (Best, The Netherlands) to offer healthcare providers worldwide a broader range of systems to diagnose and treat such diseases as cardiovascular disease and cancer. Adac's revenues for the fiscal year 2000, ended October 1, were $324.4 million.

Adac Laboratories is a leading supplier of nuclear medicine imaging equipment and radiation therapy planning systems. The nuclear medicine systems are used primarily in the diagnosis of heart disease and cancer. Adac is also a growing presence in the positron emission tomography (PET) imaging market. Adac's line will complement and broaden the Philips line of products, which include catheterization labs, magnetic resonance (MR), computed tomography (CT), x-ray, and ultrasound systems as well as information technology addressing the radiology, general imaging, and surgical and cardiovascular markets.

"In cardiology, one of our focus areas, this acquisition will significantly complement our HeartCare program since nuclear medicine is one of the important tools clinicians rely on to assess cardiovascular disease,” said Hans Barella, president and CEO of Philips Medical Systems.



Related Links:
Philips Medical Systems
Adac Laboratories
High-Precision QA Tool
DEXA Phantom
Computed Tomography System
Aquilion ONE / INSIGHT Edition
X-Ray Illuminator
X-Ray Viewbox Illuminators
Medical Radiographic X-Ray Machine
TR30N HF

Channels

Nuclear Medicine

view channel
Image: This artistic representation illustrates how the drug candidate NECT-224 works in the human body (Photo courtesy of HZDR/A. Gruetzner)

Radiopharmaceutical Molecule Marker to Improve Choice of Bladder Cancer Therapies

Targeted cancer therapies only work when tumor cells express the specific molecular structures they are designed to attack. In urothelial carcinoma, a common form of bladder cancer, the cell surface protein... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.